TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies ...Middle East

PR Newswire - News
TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
Studies suggest mechanistic benefit of guselkumab by binding to cells that drive inflammation in the colon SPRING HOUSE, Pa., March 3, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which...

Read More Details
Finally We wish PressBee provided you with enough information of ( TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies )

Apple Storegoogle play

Also on site :



Latest News